Because IFN-γ has been implicated in anti-tumor immunity and ICI therapeutic responses [61–63], we performed in vitro experiments by treating TAb2 or TCh3 tumor cell lines with varying doses of IFN-γ to determine their ability to upregulate PD-L1 in response to IFN-γ. The gene discussed is IFNG; the disease is neoplasm.